Total Payments
$203,352
2024 Payments
$6,390
Companies
13
Transactions
159
Payment Breakdown by Category
Consulting$119,986 (59.0%)
Other$33,906 (16.7%)
Research$28,364 (13.9%)
Travel$19,451 (9.6%)
Food & Beverage$1,645 (0.8%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $119,986 | 55 | 59.0% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $33,906 | 11 | 16.7% |
| Unspecified | $28,364 | 23 | 13.9% |
| Travel and Lodging | $19,451 | 40 | 9.6% |
| Food and Beverage | $1,645 | 30 | 0.8% |
Payments by Type
General
$174,988
136 transactions
Research
$28,364
23 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| SANOFI PASTEUR INC. | $76,909 | 43 | $0 (2023) |
| ModernaTX, Inc. | $55,261 | 48 | $0 (2023) |
| PFIZER INC. | $34,192 | 15 | $0 (2022) |
| Merck Sharp & Dohme LLC | $7,208 | 6 | $0 (2024) |
| GlaxoSmithKline, LLC. | $6,360 | 16 | $0 (2019) |
| AstraZeneca UK Limited | $5,771 | 9 | $0 (2023) |
| Regeneron Pharmaceuticals, Inc. | $5,114 | 6 | $0 (2017) |
| Seqirus USA Inc | $4,216 | 2 | $0 (2023) |
| Dynavax Technologies Corporation | $3,500 | 5 | $0 (2023) |
| SANOFI US SERVICES INC. | $2,000 | 1 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $6,390 | 4 | Merck Sharp & Dohme LLC ($2,790) |
| 2023 | $38,659 | 46 | ModernaTX, Inc. ($14,971) |
| 2022 | $85,876 | 48 | ModernaTX, Inc. ($39,415) |
| 2021 | $27,044 | 11 | SANOFI PASTEUR INC. ($20,169) |
| 2020 | $11,636 | 8 | SANOFI PASTEUR INC. ($11,636) |
| 2019 | $20,121 | 27 | SANOFI PASTEUR INC. ($13,310) |
| 2017 | $13,625 | 15 | SANOFI PASTEUR INC. ($7,729) |
All Payment Transactions
159 individual payment records from CMS Open Payments — Page 1 of 7
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/06/2024 | SANOFI US SERVICES INC. | — | Consulting Fee | Cash or cash equivalent | $2,000.00 | General |
| 09/09/2024 | Merck Sharp & Dohme LLC | — | Consulting Fee | Cash or cash equivalent | $930.00 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 02/07/2024 | Merck Sharp & Dohme LLC | — | Consulting Fee | Cash or cash equivalent | $1,860.00 | General |
| 01/24/2024 | AstraZeneca Pharmaceuticals LP | FLUMIST QUADRIVALENT (Biological) | Consulting Fee | Cash or cash equivalent | $1,600.00 | General |
| Category: Respiratory | ||||||
| 10/18/2023 | Merck Sharp & Dohme LLC | — | Consulting Fee | Cash or cash equivalent | $465.00 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 10/18/2023 | Merck Sharp & Dohme LLC | — | Consulting Fee | Cash or cash equivalent | $465.00 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 10/18/2023 | ModernaTX, Inc. | Moderna Covid-19 Vaccine (Biological) | Consulting Fee | Cash or cash equivalent | $390.00 | General |
| Category: Infections and Infectious Diseases | ||||||
| 09/27/2023 | ModernaTX, Inc. | — | Consulting Fee | Cash or cash equivalent | $780.00 | General |
| 09/27/2023 | ModernaTX, Inc. | — | Consulting Fee | Cash or cash equivalent | $390.00 | General |
| 09/13/2023 | Dynavax Technologies Corporation | Heplisav-B (Drug) | Consulting Fee | Cash or cash equivalent | $600.00 | General |
| Category: Hepatitis B Vaccine | ||||||
| 08/16/2023 | ModernaTX, Inc. | — | Consulting Fee | Cash or cash equivalent | $400.00 | General |
| 07/19/2023 | ModernaTX, Inc. | — | Consulting Fee | Cash or cash equivalent | $585.00 | General |
| 07/19/2023 | ModernaTX, Inc. | — | Consulting Fee | Cash or cash equivalent | $585.00 | General |
| 06/29/2023 | ModernaTX, Inc. | — | Travel and Lodging | Cash or cash equivalent | $15.15 | General |
| 06/29/2023 | ModernaTX, Inc. | — | Travel and Lodging | Cash or cash equivalent | $10.49 | General |
| 06/27/2023 | Seqirus USA Inc | FLUCELVAX QUADRIVALENT (Biological) | Consulting Fee | Cash or cash equivalent | $2,232.00 | General |
| Category: Vaccines | ||||||
| 06/27/2023 | Seqirus USA Inc | FLUCELVAX QUADRIVALENT (Biological) | Consulting Fee | Cash or cash equivalent | $1,984.00 | General |
| Category: Vaccines | ||||||
| 06/15/2023 | ModernaTX, Inc. | — | Consulting Fee | Cash or cash equivalent | $1,400.00 | General |
| 06/07/2023 | ModernaTX, Inc. | — | Consulting Fee | Cash or cash equivalent | $350.00 | General |
| 05/10/2023 | AstraZeneca UK Limited | — | Consulting Fee | Cash or cash equivalent | $2,400.00 | General |
| 05/10/2023 | Novavax Inc | — | Food and Beverage | In-kind items and services | $21.89 | General |
| 05/03/2023 | ModernaTX, Inc. | — | Consulting Fee | Cash or cash equivalent | $585.00 | General |
| 05/03/2023 | ModernaTX, Inc. | — | Consulting Fee | Cash or cash equivalent | $390.00 | General |
| 04/26/2023 | SANOFI PASTEUR INC. | — | Consulting Fee | Cash or cash equivalent | $6,216.00 | General |
| 04/26/2023 | SANOFI PASTEUR INC. | — | Travel and Lodging | Cash or cash equivalent | $68.00 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), in Adults 60 Years of Age | ModernaTX, Inc. | $6,630 | 6 |
| Phase 1/2, Randomized, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1020 and mRNA-1030 Candidate Seasonal Influenza Vaccines in Healthy Adults | ModernaTX, Inc. | $4,000 | 2 |
| A Phase 1, Randomized, Observer-Blind, Placebo-Controlled,Dose Escalation Study to Evaluate the Safety, Reactogenicity,and Immunogenicity of mRNA-1345, an mRNA VaccineTargeting Respiratory Syncytial Virus (RSV), in HealthyYounger Adults Aged | ModernaTX, Inc. | $3,325 | 4 |
| BNT162 CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $3,200 | 1 |
| COVID19 VACC CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $3,200 | 1 |
| A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age | ModernaTX, Inc. | $1,950 | 2 |
| A Study of mRNA-1647 Cytomegalovirus Vaccine in Healthy Participants 9 to 15 Years of Age and Participants 16 to 25 Years of Age | ModernaTX, Inc. | $1,950 | 2 |
| A Phase 1, Randomized, Observer-blind, Placebo-controlled, Age De-escalation Study of the Safety, Tolerability, and Immunogenicity of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months | ModernaTX, Inc. | $1,620 | 1 |
| A Phase 1, Randomized, Observer-Blind, Placebo-Controlled, Dose-Ranging Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 18- to 30-year-old Healthy Adults | ModernaTX, Inc. | $975.00 | 1 |
| A Phase 1, Randomized, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1283 and mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18-55 Years | ModernaTX, Inc. | $875.00 | 1 |
| A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults 50 Years of Age | ModernaTX, Inc. | $585.00 | 1 |
| A Phase I II, randomised, observer blind, controlled multi country study to assess the safety, reactogenicity and immunogenicity of a single intramuscular dose of GSK Biologicals investigational RSV vaccine GSK3003891A , in healthy pregnant women aged | GlaxoSmithKline, LLC. | $53.75 | 1 |
About Dr. Flor De Maria Munoz, MD
Dr. Flor De Maria Munoz, MD is a Pediatric Infectious Diseases healthcare provider based in Houston, Texas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 10/17/2006. The National Provider Identifier (NPI) number assigned to this provider is 1689754095.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Flor De Maria Munoz, MD has received a total of $203,352 in payments from pharmaceutical and medical device companies, with $6,390 received in 2024. These payments were reported across 159 transactions from 13 companies. The most common payment nature is "Consulting Fee" ($119,986).
Ad
Practice Information
- Specialty Pediatric Infectious Diseases
- Location Houston, TX
- Active Since 10/17/2006
- Last Updated 07/08/2007
- Taxonomy Code 2080P0208X
- Entity Type Individual
- NPI Number 1689754095
Products in Payments
- Moderna Covid-19 Vaccine (Biological) $21,265
- NO PRODUCT DISCUSSED (Drug) $15,349
- COMIRNATY (Biological) $6,400
- FLUZONE QUADRIVALENT (Drug) $5,690
- FLUCELVAX QUADRIVALENT (Biological) $4,216
- Heplisav-B (Drug) $3,500
- FLUZONE QUADRIVALENT NORTHERN HEMISPHERE (Biological) $3,290
- FLUMIST QUADRIVALENT (Biological) $1,600
- FLUZONE QUADRIVALENT (Biological) $1,189
- NOVAVAX COVID-19 VACCINE, ADJUVANTED (Biological) $810.00
- EVUSHELD (Drug) $571.11
- AMBISOME (Drug) $46.76
- Mycamine (Drug) $43.22
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Pediatric Infectious Diseases Doctors in Houston
Dr. Rene Amaya, Md, MD
Pediatric Infectious Diseases — Payments: $84,107
Pediatric Infectious Diseases $84,107
Carol Baker, Md, MD
Pediatric Infectious Diseases — Payments: $42,942
Pediatric Infectious Diseases $42,942
Dr. Micah Bhatti, M.d., Phd, M.D., PHD
Pediatric Infectious Diseases — Payments: $30,056
Pediatric Infectious Diseases $30,056
Gloria Heresi, M.d, M.D
Pediatric Infectious Diseases — Payments: $23,670
Pediatric Infectious Diseases $23,670
Gail Demmler, Md, MD
Pediatric Infectious Diseases — Payments: $14,888
Pediatric Infectious Diseases $14,888
Sheldon Kaplan, Md, MD
Pediatric Infectious Diseases — Payments: $14,284
Pediatric Infectious Diseases $14,284